Skip to main content
RaQualia Pharma Inc. logo

RaQualia Pharma Inc. — Investor Relations & Filings

Ticker · 4579 ISIN · JP3967150008 T Professional, scientific and technical activities
Open in API
Filings indexed 85 across all filing types
Latest filing 2026-03-23 Regulatory Filings
Country JP Japan
Listing T 4579

About RaQualia Pharma Inc.

https://www.raqualia.com/en/index.html

RaQualia Pharma Inc. is a research and development-focused pharmaceutical company that specializes in the discovery and development of innovative small molecule compounds. The company's primary activities involve conducting exploratory research to identify novel drug candidates and advancing them through preclinical and clinical studies. Its business model centers on creating value by out-licensing the intellectual property of these compounds to other pharmaceutical companies for final development and commercialization. A key product originating from its research is tegoprazan (K-CAB®), a potassium-competitive acid blocker used for treating gastroesophageal reflux disease and other acid-related conditions.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'Certification Rule', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type, as they do not contain the actual financial statements themselves. FY 18
2026-03-23 Japanese
有価証券報告書－第18期(2025/01/01－2025/12/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, management indicators, and corporate information for the fiscal year ending December 31, 2025. It is not an announcement or a summary, but the full statutory filing. FY 2025
2026-03-23 Japanese
訂正有価証券届出書（参照方式）
Capital/Financing Update Classification · 100% confidence The document is a 'Correction of Securities Registration Statement' (訂正有価証券届出書) filed with the Tokai Finance Bureau. It details a third-party allotment of shares (third-party capital increase) to HK inno.N Corporation, including the number of shares, pricing, and the intended use of proceeds for research and development and debt repayment. This falls under the category of capital and financing updates.
2025-12-19 Japanese
有価証券届出書（参照方式）
Capital/Financing Update Classification · 100% confidence The document is a '有価証券届出書' (Securities Registration Statement) filed with the Tokai Finance Bureau by RaQualia Pharma Inc. It details a third-party allotment of shares (third-party capital increase) to HK inno.N Corporation, including the number of shares, issue price, use of proceeds, and rationale for the capital raise. This document is a formal regulatory filing related to capital structure changes and financing activities, which falls under the 'Capital/Financing Update' category.
2025-12-12 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-5-2 of the Financial Instruments and Exchange Act of Japan, accompanying a semi-annual report (Second Quarter Report). It confirms the accuracy of the financial reporting for the period ending June 30, 2025. Since it is a regulatory filing required by law to accompany financial reports and does not fit into the specific categories of the reports themselves, it is classified as a Regulatory Filing.
2025-08-14 Japanese
半期報告書－第18期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Tokai Local Finance Bureau under the Financial Instruments and Exchange Act of Japan. It covers the fiscal period from January 1, 2025, to June 30, 2025. It contains comprehensive financial statements, management analysis (MDA), and corporate information. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.